KB
KERX

Kimelman & Baird’s Keryx Biopharmaceuticals Inc KERX Stock Holding History

Kimelman & Baird’s Portfolio KERX Stock Details KERX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q2 		– Sell
-10,000
Closed -$127K – 125
2015
Q1 		$127K Hold
10,000
– – 0.02% 111
2014
Q4 		$141K Hold
10,000
– – 0.03% 114
2014
Q3 		$137K Hold
10,000
– – 0.03% 108
2014
Q2 		$154K Hold
10,000
– – 0.03% 109
2014
Q1 		$170K Hold
10,000
– – 0.03% 106
2013
Q4 		$129K Hold
10,000
– – 0.02% 99
2013
Q3 		$101K Hold
10,000
– – 0.02% 95
2013
Q2 		$75K Buy
+10,000
New +$78.1K 0.02% 93

Other funds holding KERX

BG
Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BGIM
Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return

Kimelman & Baird's KERX Position: Q2 2015 in Review

Kimelman & Baird sold out of Keryx Biopharmaceuticals Inc (KERX) in Q2 2015, closing a stake of 10,000 shares — an estimated $127K sold.

Kimelman & Baird first reported a position in KERX in Q2 2013 and held it in 8 quarters. The position peaked at $170K in Q1 2014. 153 funds tracked by Wall St. Rank hold KERX as of Q2 2015.

  • Kimelman & Baird reported no remaining Keryx Biopharmaceuticals Inc position as of Q2 2015 after selling out during the quarter.
  • Kimelman & Baird sold 10,000 Keryx Biopharmaceuticals Inc shares in Q2 2015, an estimated $127K.
  • Kimelman & Baird first reported a position in Keryx Biopharmaceuticals Inc in Q2 2013 and held it in 8 quarters.
  • Kimelman & Baird's Keryx Biopharmaceuticals Inc position peaked at $170K in Q1 2014.
  • 153 funds tracked by Wall St. Rank held Keryx Biopharmaceuticals Inc as of Q2 2015.

Based on Kimelman & Baird's 13F filing for Q2 2015, filed 12 Aug 2015.